Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Miyata Eye Hospital, Miyazaki, Japan.
PLoS One. 2018 May 10;13(5):e0197042. doi: 10.1371/journal.pone.0197042. eCollection 2018.
To investigate the relationship between choroidal structure and visual acuity after intravitreal aflibercept therapy for polypoidal choroidal vasculopathy (PCV).
We conducted a retrospective, single-centre and observational study including 18 eyes of 18 patients with PCV (73.8 ± 10.2 years of age) who were treated with three monthly intravitreal aflibercept injections followed by additional treatments in a treat-and-extend protocol. The cross-sectional images of the macula were obtained with enhanced depth imaging optical coherence tomography at baseline, at 3 months, and at 12 months. The choroidal layer was divided into luminal or stromal segments by applying binarization processing to calculate these areas. The relationships between age, spherical equivalent, best-corrected visual acuity (BCVA), baseline value, or changes in the luminal or the stromal areas, and the BCVA change at 12 months were analysed using multiple regression analyses and model selection procedures.
Both stromal and luminal areas were decreased at 3 and 12 months compared to baseline areas (5% and 9% at 3 months, 6% and 12% at 12 months, p < 0.0001, p < 0.0001, p < 0.0001 and p < 0.0001, respectively). Greater improvement of visual acuity (VA) at 12 months was significantly associated with younger age, greater spherical equivalent, worse baseline BCVA, greater baseline luminal area, and smaller baseline stromal area.
Choroidal structure might be useful as a new biomarker for potential Visual outcomes after intravitreal aflibercept therapy for PCV.
研究玻璃体内注射阿柏西普治疗息肉样脉络膜血管病变（PCV）后脉络膜结构与视力的关系。
我们进行了一项回顾性、单中心和观察性研究，纳入了 18 例（73.8±10.2 岁）PCV 患者的 18 只眼，这些患者接受了三次每月玻璃体内注射阿柏西普治疗，随后根据治疗和扩展方案进行了额外的治疗。在基线、3 个月和 12 个月时，使用增强深度成像光相干断层扫描获得黄斑的横截面图像。通过对图像进行二值化处理，将脉络膜层分为管腔或基质节段，以计算这些区域的面积。使用多元回归分析和模型选择程序分析年龄、等效球镜、最佳矫正视力（BCVA）、基线值或管腔和基质区域的变化与 12 个月时 BCVA 变化之间的关系。
与基线面积相比，3 个月和 12 个月时基质和管腔面积均减少（3 个月时分别为 5%和 9%，12 个月时分别为 6%和 12%，p<0.0001，p<0.0001，p<0.0001 和 p<0.0001）。12 个月时视力（VA）改善更大与年龄较小、等效球镜较大、基线 BCVA 较差、基线管腔面积较大和基线基质面积较小显著相关。
脉络膜结构可能是玻璃体内注射阿柏西普治疗 PCV 后潜在视力结果的一个新的生物标志物。
